» Articles » PMID: 10869773

Antibody Response to Influenza Immunization in Two Consecutive Epidemic Seasons in Patients with Renal Diseases

Overview
Journal Vaccine
Date 2000 Jun 28
PMID 10869773
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to assess antihemagglutinin and antineuraminidase antibody kinetics in 26 patients with renal diseases vaccinated against influenza in two consecutive epidemic seasons. Antibody responses were measured before immunization and 1, 3 and 6 months after immunization. Antihemagglutinin (HI) antibodies were determined by the hemagglutinin inhibition test and antineuraminidase (NI) antibody levels by the neuraminidase inhibition test. After vaccination HI and NI antibody titers significantly increased when compared with the pre-vaccination levels. Three months after vaccination the protection rates ranged from 50 to 61.5% in the 1995/96 season and 100% for all antigens in the 1996/97 season. Response rates ranged from 50 to 57.7% and 93.8 to 100% respectively. Significantly higher humoral response was recorded in the 1996/97 season than in the 1995/96 season. No serious adverse reactions were observed in the vaccinated patients and no symptoms of influenza or influenza-like infection were noted. In spite of some doubts about the safety and efficacy of influenza vaccination in patients from high-risk groups, the results of this study showed that many of them are able to produce HI antibodies in titers which are sufficient to protect against the influenza infection.

Citing Articles

Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccine Among Patients Receiving Maintenance Hemodialysis.

Butler A, Layton J, Dharnidharka V, Sahrmann J, Seamans M, Weber D Am J Kidney Dis. 2019; 75(1):72-83.

PMID: 31378646 PMC: 6926162. DOI: 10.1053/j.ajkd.2019.05.018.


Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.

Schwarz T, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M J Infect Dis. 2017; 216(11):1352-1361.

PMID: 29029224 PMC: 5853904. DOI: 10.1093/infdis/jix481.


The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects.

Haralambieva I, Painter S, Kennedy R, Ovsyannikova I, Lambert N, Goergen K PLoS One. 2015; 10(3):e0122282.

PMID: 25816015 PMC: 4376784. DOI: 10.1371/journal.pone.0122282.


Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety.

Remschmidt C, Wichmann O, Harder T BMC Med. 2014; 12:244.

PMID: 25523432 PMC: 4298993. DOI: 10.1186/s12916-014-0244-9.


Long-term safety of immunomodulators in pediatric inflammatory diseases.

Nuti F, Civitelli F, Cucchiara S Paediatr Drugs. 2014; 16(5):343-52.

PMID: 25047730 DOI: 10.1007/s40272-014-0084-2.